The treatment for adolescents with depression study (TADS)

Outcomes over 1 year of naturalistic follow-up

John March*, Susan Silva, John Curry, Karen Wells, John Fairbank, Barbara Burns, Marisa Domino, Benedetto Vitiello, Joanne Severe, Charles Casat, Karyn Riedal, Marguerita Goldman, Norah Feeny, Robert Findling, Sheridan Stull, Susan Baab, Elizabeth B. Weller, Michele Robins, Ronald A. Weller, Naushad Jessani & 35 others Bruce Waslick, Michael Sweeney, Randi Dublin, John Walkup, Golda Ginsburg, Elizabeth Kastelic, Hyung Koo, Christopher Kratochvil, Diane May, Randy LaGrone, Brigette Vaughan, Anne Marie Albano, Glenn S. Hirsch, Elizabeth Podniesinki, Angela Chu, Mark Reinecke, Bennett Leventhal, Gregory Rogers, Rachel Jacobs, Sanjeev Pathak, Jennifer Wells, Sarah A. Lavanier, Arman Danielyan, Paul Rohde, Anne Simons, James Grimm, Stephenie Frank, Graham Emslie, Beth Kennard, Carroll Hughes, Taryn L. Mayes, David Rosenberg, Nili Benazon, Michael Butkus, Marla Bartoi

*Corresponding author for this work

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Objective: The Treatment for Adolescents With Depression Study (TADS) evaluates the effectiveness of fluoxetine, cognitive-behavioral therapy (CBT), and their combination in adolescents with major depressive disorder. The authors report effectiveness outcomes across a 1-year naturalistic follow-up period. Method: The randomized, controlled trial was conducted in 13 academic and community sites in the United States. Stages I, II, and III consisted of 12, 6, and 18 weeks of acute, consolidation, and continuation treatment, respectively. Following discontinuation of TADS treatments at the end of stage III, stage IV consisted of 1 year of naturalistic follow-up. The participants were 327 subjects between the ages of 12 and 17 with a primary DSM-IV diagnosis of major depressive disorder. No TADS treatment was provided during the follow-up period; treatment was available in the community. The primary dependent measures, rated by an independent evaluator blind to treatment status, were the total score on the Children's Depression Rating Scale - Revised and the rate of response, defined as a rating of much or very much improved on the Clinical Global Impressions improvement measure. Results: Sixty-six percent of the eligible subjects participated in at least one stage IV assessment. The benefits seen at the end of active treatment (week 36) persisted during follow-up on all measures of depression and suicidality. Conclusions: In contrast to earlier reports on short-term treatments, in which worsening after treatment is the rule, the longer treatment in the TADS was associated with persistent benefits over 1 year of naturalistic follow-up.

Original languageEnglish (US)
Pages (from-to)1141-1149
Number of pages9
JournalAmerican Journal of Psychiatry
Volume166
Issue number10
DOIs
StatePublished - Oct 1 2009

Fingerprint

Outcome Assessment (Health Care)
Depression
Therapeutics
Major Depressive Disorder
Fluoxetine
Cognitive Therapy
Diagnostic and Statistical Manual of Mental Disorders
Randomized Controlled Trials

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

March, John ; Silva, Susan ; Curry, John ; Wells, Karen ; Fairbank, John ; Burns, Barbara ; Domino, Marisa ; Vitiello, Benedetto ; Severe, Joanne ; Casat, Charles ; Riedal, Karyn ; Goldman, Marguerita ; Feeny, Norah ; Findling, Robert ; Stull, Sheridan ; Baab, Susan ; Weller, Elizabeth B. ; Robins, Michele ; Weller, Ronald A. ; Jessani, Naushad ; Waslick, Bruce ; Sweeney, Michael ; Dublin, Randi ; Walkup, John ; Ginsburg, Golda ; Kastelic, Elizabeth ; Koo, Hyung ; Kratochvil, Christopher ; May, Diane ; LaGrone, Randy ; Vaughan, Brigette ; Albano, Anne Marie ; Hirsch, Glenn S. ; Podniesinki, Elizabeth ; Chu, Angela ; Reinecke, Mark ; Leventhal, Bennett ; Rogers, Gregory ; Jacobs, Rachel ; Pathak, Sanjeev ; Wells, Jennifer ; Lavanier, Sarah A. ; Danielyan, Arman ; Rohde, Paul ; Simons, Anne ; Grimm, James ; Frank, Stephenie ; Emslie, Graham ; Kennard, Beth ; Hughes, Carroll ; Mayes, Taryn L. ; Rosenberg, David ; Benazon, Nili ; Butkus, Michael ; Bartoi, Marla. / The treatment for adolescents with depression study (TADS) : Outcomes over 1 year of naturalistic follow-up. In: American Journal of Psychiatry. 2009 ; Vol. 166, No. 10. pp. 1141-1149.
@article{9dea947c671f45c3b28b8746934b7433,
title = "The treatment for adolescents with depression study (TADS): Outcomes over 1 year of naturalistic follow-up",
abstract = "Objective: The Treatment for Adolescents With Depression Study (TADS) evaluates the effectiveness of fluoxetine, cognitive-behavioral therapy (CBT), and their combination in adolescents with major depressive disorder. The authors report effectiveness outcomes across a 1-year naturalistic follow-up period. Method: The randomized, controlled trial was conducted in 13 academic and community sites in the United States. Stages I, II, and III consisted of 12, 6, and 18 weeks of acute, consolidation, and continuation treatment, respectively. Following discontinuation of TADS treatments at the end of stage III, stage IV consisted of 1 year of naturalistic follow-up. The participants were 327 subjects between the ages of 12 and 17 with a primary DSM-IV diagnosis of major depressive disorder. No TADS treatment was provided during the follow-up period; treatment was available in the community. The primary dependent measures, rated by an independent evaluator blind to treatment status, were the total score on the Children's Depression Rating Scale - Revised and the rate of response, defined as a rating of much or very much improved on the Clinical Global Impressions improvement measure. Results: Sixty-six percent of the eligible subjects participated in at least one stage IV assessment. The benefits seen at the end of active treatment (week 36) persisted during follow-up on all measures of depression and suicidality. Conclusions: In contrast to earlier reports on short-term treatments, in which worsening after treatment is the rule, the longer treatment in the TADS was associated with persistent benefits over 1 year of naturalistic follow-up.",
author = "John March and Susan Silva and John Curry and Karen Wells and John Fairbank and Barbara Burns and Marisa Domino and Benedetto Vitiello and Joanne Severe and Charles Casat and Karyn Riedal and Marguerita Goldman and Norah Feeny and Robert Findling and Sheridan Stull and Susan Baab and Weller, {Elizabeth B.} and Michele Robins and Weller, {Ronald A.} and Naushad Jessani and Bruce Waslick and Michael Sweeney and Randi Dublin and John Walkup and Golda Ginsburg and Elizabeth Kastelic and Hyung Koo and Christopher Kratochvil and Diane May and Randy LaGrone and Brigette Vaughan and Albano, {Anne Marie} and Hirsch, {Glenn S.} and Elizabeth Podniesinki and Angela Chu and Mark Reinecke and Bennett Leventhal and Gregory Rogers and Rachel Jacobs and Sanjeev Pathak and Jennifer Wells and Lavanier, {Sarah A.} and Arman Danielyan and Paul Rohde and Anne Simons and James Grimm and Stephenie Frank and Graham Emslie and Beth Kennard and Carroll Hughes and Mayes, {Taryn L.} and David Rosenberg and Nili Benazon and Michael Butkus and Marla Bartoi",
year = "2009",
month = "10",
day = "1",
doi = "10.1176/appi.ajp.2009.08111620",
language = "English (US)",
volume = "166",
pages = "1141--1149",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "10",

}

March, J, Silva, S, Curry, J, Wells, K, Fairbank, J, Burns, B, Domino, M, Vitiello, B, Severe, J, Casat, C, Riedal, K, Goldman, M, Feeny, N, Findling, R, Stull, S, Baab, S, Weller, EB, Robins, M, Weller, RA, Jessani, N, Waslick, B, Sweeney, M, Dublin, R, Walkup, J, Ginsburg, G, Kastelic, E, Koo, H, Kratochvil, C, May, D, LaGrone, R, Vaughan, B, Albano, AM, Hirsch, GS, Podniesinki, E, Chu, A, Reinecke, M, Leventhal, B, Rogers, G, Jacobs, R, Pathak, S, Wells, J, Lavanier, SA, Danielyan, A, Rohde, P, Simons, A, Grimm, J, Frank, S, Emslie, G, Kennard, B, Hughes, C, Mayes, TL, Rosenberg, D, Benazon, N, Butkus, M & Bartoi, M 2009, 'The treatment for adolescents with depression study (TADS): Outcomes over 1 year of naturalistic follow-up', American Journal of Psychiatry, vol. 166, no. 10, pp. 1141-1149. https://doi.org/10.1176/appi.ajp.2009.08111620

The treatment for adolescents with depression study (TADS) : Outcomes over 1 year of naturalistic follow-up. / March, John; Silva, Susan; Curry, John; Wells, Karen; Fairbank, John; Burns, Barbara; Domino, Marisa; Vitiello, Benedetto; Severe, Joanne; Casat, Charles; Riedal, Karyn; Goldman, Marguerita; Feeny, Norah; Findling, Robert; Stull, Sheridan; Baab, Susan; Weller, Elizabeth B.; Robins, Michele; Weller, Ronald A.; Jessani, Naushad; Waslick, Bruce; Sweeney, Michael; Dublin, Randi; Walkup, John; Ginsburg, Golda; Kastelic, Elizabeth; Koo, Hyung; Kratochvil, Christopher; May, Diane; LaGrone, Randy; Vaughan, Brigette; Albano, Anne Marie; Hirsch, Glenn S.; Podniesinki, Elizabeth; Chu, Angela; Reinecke, Mark; Leventhal, Bennett; Rogers, Gregory; Jacobs, Rachel; Pathak, Sanjeev; Wells, Jennifer; Lavanier, Sarah A.; Danielyan, Arman; Rohde, Paul; Simons, Anne; Grimm, James; Frank, Stephenie; Emslie, Graham; Kennard, Beth; Hughes, Carroll; Mayes, Taryn L.; Rosenberg, David; Benazon, Nili; Butkus, Michael; Bartoi, Marla.

In: American Journal of Psychiatry, Vol. 166, No. 10, 01.10.2009, p. 1141-1149.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The treatment for adolescents with depression study (TADS)

T2 - Outcomes over 1 year of naturalistic follow-up

AU - March, John

AU - Silva, Susan

AU - Curry, John

AU - Wells, Karen

AU - Fairbank, John

AU - Burns, Barbara

AU - Domino, Marisa

AU - Vitiello, Benedetto

AU - Severe, Joanne

AU - Casat, Charles

AU - Riedal, Karyn

AU - Goldman, Marguerita

AU - Feeny, Norah

AU - Findling, Robert

AU - Stull, Sheridan

AU - Baab, Susan

AU - Weller, Elizabeth B.

AU - Robins, Michele

AU - Weller, Ronald A.

AU - Jessani, Naushad

AU - Waslick, Bruce

AU - Sweeney, Michael

AU - Dublin, Randi

AU - Walkup, John

AU - Ginsburg, Golda

AU - Kastelic, Elizabeth

AU - Koo, Hyung

AU - Kratochvil, Christopher

AU - May, Diane

AU - LaGrone, Randy

AU - Vaughan, Brigette

AU - Albano, Anne Marie

AU - Hirsch, Glenn S.

AU - Podniesinki, Elizabeth

AU - Chu, Angela

AU - Reinecke, Mark

AU - Leventhal, Bennett

AU - Rogers, Gregory

AU - Jacobs, Rachel

AU - Pathak, Sanjeev

AU - Wells, Jennifer

AU - Lavanier, Sarah A.

AU - Danielyan, Arman

AU - Rohde, Paul

AU - Simons, Anne

AU - Grimm, James

AU - Frank, Stephenie

AU - Emslie, Graham

AU - Kennard, Beth

AU - Hughes, Carroll

AU - Mayes, Taryn L.

AU - Rosenberg, David

AU - Benazon, Nili

AU - Butkus, Michael

AU - Bartoi, Marla

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Objective: The Treatment for Adolescents With Depression Study (TADS) evaluates the effectiveness of fluoxetine, cognitive-behavioral therapy (CBT), and their combination in adolescents with major depressive disorder. The authors report effectiveness outcomes across a 1-year naturalistic follow-up period. Method: The randomized, controlled trial was conducted in 13 academic and community sites in the United States. Stages I, II, and III consisted of 12, 6, and 18 weeks of acute, consolidation, and continuation treatment, respectively. Following discontinuation of TADS treatments at the end of stage III, stage IV consisted of 1 year of naturalistic follow-up. The participants were 327 subjects between the ages of 12 and 17 with a primary DSM-IV diagnosis of major depressive disorder. No TADS treatment was provided during the follow-up period; treatment was available in the community. The primary dependent measures, rated by an independent evaluator blind to treatment status, were the total score on the Children's Depression Rating Scale - Revised and the rate of response, defined as a rating of much or very much improved on the Clinical Global Impressions improvement measure. Results: Sixty-six percent of the eligible subjects participated in at least one stage IV assessment. The benefits seen at the end of active treatment (week 36) persisted during follow-up on all measures of depression and suicidality. Conclusions: In contrast to earlier reports on short-term treatments, in which worsening after treatment is the rule, the longer treatment in the TADS was associated with persistent benefits over 1 year of naturalistic follow-up.

AB - Objective: The Treatment for Adolescents With Depression Study (TADS) evaluates the effectiveness of fluoxetine, cognitive-behavioral therapy (CBT), and their combination in adolescents with major depressive disorder. The authors report effectiveness outcomes across a 1-year naturalistic follow-up period. Method: The randomized, controlled trial was conducted in 13 academic and community sites in the United States. Stages I, II, and III consisted of 12, 6, and 18 weeks of acute, consolidation, and continuation treatment, respectively. Following discontinuation of TADS treatments at the end of stage III, stage IV consisted of 1 year of naturalistic follow-up. The participants were 327 subjects between the ages of 12 and 17 with a primary DSM-IV diagnosis of major depressive disorder. No TADS treatment was provided during the follow-up period; treatment was available in the community. The primary dependent measures, rated by an independent evaluator blind to treatment status, were the total score on the Children's Depression Rating Scale - Revised and the rate of response, defined as a rating of much or very much improved on the Clinical Global Impressions improvement measure. Results: Sixty-six percent of the eligible subjects participated in at least one stage IV assessment. The benefits seen at the end of active treatment (week 36) persisted during follow-up on all measures of depression and suicidality. Conclusions: In contrast to earlier reports on short-term treatments, in which worsening after treatment is the rule, the longer treatment in the TADS was associated with persistent benefits over 1 year of naturalistic follow-up.

UR - http://www.scopus.com/inward/record.url?scp=70349638431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349638431&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.2009.08111620

DO - 10.1176/appi.ajp.2009.08111620

M3 - Article

VL - 166

SP - 1141

EP - 1149

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 10

ER -